Mode and site of action of therapies targeting CGRP signaling

Alejandro Labastida-Ramírez; Edoardo Caronna; Cédric Gollion; Emily Stanyer; Austeja Dapkute; Diana Braniste; Hoda Naghshineh; Līga Mekša; Nino Chkhitunidze; Tamari Gudadze; Patricia Pozo-Rosich; Rami Burstein; Jan Hoffmann

doi:10.1186/s10194-023-01644-8

Mode and site of action of therapies targeting CGRP signaling

Alejandro Labastida-Ramírez
, Edoardo Caronna
, Cédric Gollion
, Emily Stanyer
, Austeja Dapkute
, Diana Braniste
, Hoda Naghshineh
, Līga Mekša
, Nino Chkhitunidze
, Tamari Gudadze
, Patricia Pozo-Rosich
, Rami Burstein
, Jan Hoffmann (Corresponding Author)

Research output: Contribution to journal › Review article › peer-review

51 Citations (Scopus)

Abstract

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.

Original language	English
Article number	125
Journal	Journal of Headache and Pain
Volume	24
Issue number	1
DOIs	https://doi.org/10.1186/s10194-023-01644-8
Publication status	Published - 11 Sept 2023
Externally published	Yes

Keywords*

Amylin
Anti-CGRP
Calcitonin
Headache
Migraine
Trigeminal

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1186/s10194-023-01644-8Licence: CC BY

Mode and site of action of therapiesFinal published version, 1.3 MBLicence: CC BY

Cite this

@article{1e67ed2c27f74398a2a7187443e4f148,

title = "Mode and site of action of therapies targeting CGRP signaling",

abstract = "Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.",

keywords = "Amylin, Anti-CGRP, Calcitonin, Headache, Migraine, Trigeminal",

author = "Alejandro Labastida-Ram{\'i}rez and Edoardo Caronna and C{\'e}dric Gollion and Emily Stanyer and Austeja Dapkute and Diana Braniste and Hoda Naghshineh and Līga Mek{\v s}a and Nino Chkhitunidze and Tamari Gudadze and Patricia Pozo-Rosich and Rami Burstein and Jan Hoffmann",

note = "Publisher Copyright: {\textcopyright} 2023, Springer-Verlag Italia S.r.l., part of Springer Nature.",

year = "2023",

month = sep,

day = "11",

doi = "10.1186/s10194-023-01644-8",

language = "English",

volume = "24",

journal = "Journal of Headache and Pain",

issn = "1129-2369",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Mode and site of action of therapies targeting CGRP signaling

AU - Labastida-Ramírez, Alejandro

AU - Caronna, Edoardo

AU - Gollion, Cédric

AU - Stanyer, Emily

AU - Dapkute, Austeja

AU - Braniste, Diana

AU - Naghshineh, Hoda

AU - Mekša, Līga

AU - Chkhitunidze, Nino

AU - Gudadze, Tamari

AU - Pozo-Rosich, Patricia

AU - Burstein, Rami

AU - Hoffmann, Jan

PY - 2023/9/11

Y1 - 2023/9/11

N2 - Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.

AB - Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.

KW - Amylin

KW - Anti-CGRP

KW - Calcitonin

KW - Headache

KW - Migraine

KW - Trigeminal

UR - https://www.scopus.com/pages/publications/85170379299

U2 - 10.1186/s10194-023-01644-8

DO - 10.1186/s10194-023-01644-8

M3 - Review article

C2 - 37691118

AN - SCOPUS:85170379299

SN - 1129-2369

VL - 24

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

IS - 1

M1 - 125

ER -

Mode and site of action of therapies targeting CGRP signaling

Abstract

Keywords*

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this